BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30

$78.17−1.37 (-1.72%)

Close on Nov 12, 2026Market cap $15.23BP/E –Yield –

BridgeBio Pharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-16.1%	–
Q3 FY2025	Sep 30, 2025	-151.4%	–

Parsed from the XBRL in BridgeBio Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBIO.

Revenue growth167.3% · median -0.7%

Gross margin94.3% · median 90.2%

Operating margin-38.5% · median -2.5%

Advertisement
300 × 250

See a number that looks wrong?